Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 35 of 53 · 2518 articles
This study shows a mechanism by which IL-10 protects gut epithelial mitochondria and barrier function during exposure to an IBD-associated E. coli strain, which could be relevant to understanding pathways that maintain...
The study suggests a new host-directed mechanism that helps a common beneficial gut bacterium (Faecalibacterium prausnitzii) colonize and protect the gut lining, and identifies heparan sulfate as a potential way to...
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
This large, population-based study suggests people with Crohn's disease have modestly higher overall mortality than matched controls and higher deaths from specific causes (colorectal cancer, renal disease, non-Hodgkin...
People using upadacitinib for Crohn’s disease or ulcerative colitis should be aware of a newly reported, reversible semen discoloration that may be dose-related. This could be concerning for patients and affect...
The study suggests that while Crohn's disease produces a shared dysbiotic signature at diagnosis, the specific microbes enriched differ by age — notably oral-associated taxa in children — which could affect research into...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gut and liver.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Researchers used machine learning to prioritize microbiome-related regulatory targets in Crohn's disease, which may guide future lab and clinical research into microbial pathways (like butyrate-related metabolism) that...
People with Crohn’s disease can have liver involvement that may be missed on routine exams. Quantitative liver MRI measures (fat fraction and extracellular volume) could help detect and monitor subtle liver injury...
The study links a common commensal fungus, Candida albicans, to a focused Th17 immune response that can turn harmful in Crohn’s disease, identifying a specific cell population that could be targeted more precisely than...
Energy depletion, poor sleep, and stress are common in Crohn’s disease and can worsen quality of life. Practical self-care strategies may help patients feel better day-to-day when used alongside medical treatment.
Low energy and fatigue are common in Crohn’s disease and can come from active inflammation, poor sleep, low appetite, or the emotional toll of a chronic illness. Practical lifestyle strategies may help patients feel...
People with IBD who also have bleeding disorders face special risks during endoscopy, surgery, and when using immunosuppressive drugs. This case shows that coordinated care and hemostatic support can allow diagnosis and...
Cure8 found this source from Endokrynologia Polska, but the page could not be read reliably yet. It is tagged for Crohn's disease, Abdominal Pain, and Tests and monitoring. Open the original article for the full details.
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with Crohn's disease commonly experience menstrual cramps, but there is little trial evidence comparing common OTC pain medicines in this group. This pilot trial aims to test whether a larger randomized study is...
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
The gut microbiome differed more in pediatric Crohn’s disease and acute pancreatitis than in IBS or healthy kids, suggesting microbial changes are stronger in organic inflammatory disease and could be targets for future...
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
Cure8 found this source from American journal of therapeutics, but the page could not be read reliably yet. It is tagged for Crohn's disease, Infliximab, and Anti-TNF. Open the original article for the full details.
Identifies features associated with the new international definition of difficult‑to‑treat Crohn’s disease and links DTT status to greater mental fatigue. Biomarker differences (IL‑5, IL‑10) may point to distinct immune...
Fatigue affects many people with Crohn’s even when inflammation looks controlled; recognizing it as a distinct target could change clinic assessments and treatment priorities.
Patients with small-bowel strictures face repeat procedures or surgery; this study suggests endoscopic stricturotomy outcomes differ by whether the stricture is from Crohn’s disease and that a simple blood marker (NLR)...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Alimentary pharmacology &...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from European radiology.
The study suggests that being symptom-free doesn’t guarantee the gut’s microbiome, metabolome, or epithelial functions have returned to a healthy state. Diet—especially ultraprocessed-food intake—was linked to persistent...
The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
Bile acids shape immune signaling in the gut, and this project investigates how altered bile acid pools during ileitis could contribute to Crohn’s disease—knowledge that might point to new biomarkers or treatment...
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
An FDA label update names risankizumab (SKYRIZI) as a treatment option for adults with moderately to severely active Crohn’s disease and ulcerative colitis and highlights new or emphasized safety monitoring (liver tests,...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....
FUT enzymes affect mucosal immunity and have been associated with Crohn's disease and other IBDs; understanding their function could reveal new biological mechanisms and future therapeutic targets.
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves...
A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.
